About 85% of lung cancer patients suffer from NSCLC (non-small cell lung cancer), of which about 5% are ALK positive. ALK+NSCLC is caused by a gene fusion or rearrangement that over-activates the ALK protein, which is conducive to cancer cell growth and survival. ALK+NSCLC is a distinct cancer type commonly found in relatively younger lung cancer groups (at a median age of 52 years old) with no history of smoking. 50% in the groups are younger than 50 years old and approximately 70% in the groups have never smoked.

ALK inhibitors can suppress tumor growth by effectively disabling ALK activity. Among the ALK inhibitors that have been marketed, alectinib is one of the superior drugs.

Alectinib, originally developed by Roche, was first approved by the FDA on December 11, 2015, for patients with crizotinib-resistant ALK-positive non-small cell lung cancer. on November 6, 2017, the FDA also approved alectinib as a first-line agent for ALK-positive patients. Phase III clinical trials comparing alectinib and crizotinib for the first-line treatment of ALK-positive lung cancer patients showed that alectinib could significantly reduce the risk of disease progression or death by up to 57%, prolong patient disease-free survival by up to 34.8 months and delay brain metastases.

Because of the favorable efficacy of alectinib, authoritative guidelines at home and abroad like NCCN Guidelines 2019, CSCO Guidelines 2019 and ESMO Guidelines 2019 have unanimously recommended alectinib as a first-line priority for patients with ALK+ NSCLC.

According to CRI’s market research, Roche’s alectinib (trade name: Alecensa^®, manufactured by Excella GmbH & Co. KG) was approved for marketing in China in August 2018 for the indication of monotherapy of ALK-positive patients with locally advanced or metastatic NSCLC.

In the China National Reimbursement Drug List Negotiation 2019, Alectinib (only Alecensa is available in China as of August 2021) was included in the Category B of the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, which came into effect on 1 January, 2020. In the Chinese market, a one-month dose of alectinib (150mg *224 capsules) cost CNY49,980 (USD7,690) before 2020. Then from 1 January, 2020, the price has reduced by more than 60%. However, for most Chinese patients, the monthly expenditure of approximately CNY15,230 (USD2,340) on alectinib is still too high. Since the annual disposable income per capita in China was only CNY32,189 (USD4,952) in 2020, which means the monthly disposable income per capita was less than USD500, there are still many Chinese patients cannot afford to purchase alectinib.

According to CRI’s market research, the sales value of alectinib in the Chinese market reached approximately CNY307 million (USD47.18 million) in 2020, with a CAGR of 815% from 2018 to 2020. The COVID-19 outbreak in early 2020 posed certain impact on the Chinese healthcare industry, but had minimal impact on its alectinib market.

CRI expects that, from 2021 to 2025, new cases of lung cancer in China will continue to grow as a result of environmental pollution and poor lifestyles. And with the growing income of Chinese residents, there are able to pay more for medical expenses. Therefore, China’s alectinib market is expected to grow in both sales volume and value during this period. Local Chinese pharmaceutical companies may also accelerate the production of generic alectinib drugs, but due to the great difficulty in production, it is expected that generic alectinib drugs from local Chinese pharmaceutical companies will not be available until around 2025 at the earliest.

Topics Covered:

• Impact of COVID-19 on China’s Alectinib Market
• Development Environment of Alectinib in China
• Sales Volume of Alectinib in China
• Sales Volume and Value of Alectinib in China by Region
• Major Alectinib Manufacturers in China and Their Market Shares
• Sales Price of Alectinib in China
• Prospects of China’s Alectinib Market, 2021-2025

Related reports:

Research Report on China’s Gefitinib Market, 2021-2025

The post Research Report on China’s Alectinib Market, 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital’s overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.

CRI expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Capecitabine market
• – Sales value of China’s Capecitabine 2016-2020
• – Competitive landscape of China’s Capecitabine market
• – Prices of Capecitabine in China
• – Prices of Capecitabine in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Capecitabine market
• – Prospect of China’s Capecitabine market from 2021 to 2025

The post Investigation Report on China’s Capecitabine Market 2021-2025 first appeared on CRI Report.

Mycophenolate mofetil was developed by Roche Pharmaceuticals Co., Ltd., and the trade name of Mycophenolate mofetil from Roche is CELLCEPT. CELLCEPT was first approved by the NMPA for listing in China in 2004, and then generic drugs from local Chinese companies have also been listed successively. By 2020, there are many manufacturers in China’s mycophenolate mofetil market, among which Shanghai Roche Pharmaceuticals Co., Ltd. has the highest sales market share.

According to CRI’s research market, the sales of mycophenolate mofetil in the Chinese market have increased year by year from 2016 to 2020. In 2020, due to the impact of the Covid-19 epidemic on the overall medical diagnosis and treatment services, the growth rate of sales has decreased. However, the sales still reached CNY 921 million, with a CAGR of 6.54% from 2016 to 2020.

CRI expects that with the effective alleviation of the Covid-19 epidemic, the sales of mycophenolate mofetil in the Chinese market will have a restorative growth from 2021 to 2025. At the same time, compared with similar drugs, mycophenolate mofetil is safer and more effective. Based on these advantages, the sales volume and sales of mycophenolate mofetil in the Chinese market will continue to grow from 2021 to 2025.

Topics Covered:

-The impact of COVID-19 on China’s Mycophenolate Mofetil market

– Sales value of China’s Mycophenolate Mofetil 2016-2020

– Competitive landscape of China’s Mycophenolate Mofetil market

– Prices of Mycophenolate Mofetil in China

– Prices of Mycophenolate Mofetil in China by regions and manufacturers

– Analysis on factors affecting the development of China’s Mycophenolate Mofetil market

– Prospect of China’s Mycophenolate Mofetil market from 2021 to 2025

The post Investigation Report on China’s Mycophenolate Mofetil Market 2021-2025 first appeared on CRI Report.